21-1430
烟酸
SAJ special grade, ≥99.5%
别名:
3-吡啶甲酸, 吡啶-3-羧酸, 尼亚生, 抗糙皮病因子, 维生素 B3
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C6H5NO2
化学文摘社编号:
分子量:
123.11
EC Number:
200-441-0
UNSPSC Code:
12352005
PubChem Substance ID:
Beilstein/REAXYS Number:
109591
MDL number:
InChI key
PVNIIMVLHYAWGP-UHFFFAOYSA-N
InChI
1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)
SMILES string
OC(=O)c1cccnc1
grade
SAJ special grade
assay
≥99.5%
form
powder
availability
available only in Japan
color
white
mp
236-239 °C (lit.)
solubility
ethanol: 12.5 g/L at 25 °C, water: soluble 180 g/L at 20 °C
density
1.473 g/cm3 at 25 °C
正在寻找类似产品? 访问 产品对比指南
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
379.4 °F - closed cup
flash_point_c
193 °C - closed cup
ppe
dust mask type N95 (US), Eyeshields, Gloves
法规信息
新产品
此项目有
Koon K Teo et al.
Stroke, 44(10), 2688-2693 (2013-07-25)
In Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, addition of extended-release niacin (ERN) to simvastatin in participants with established cardiovascular disease, low high-density lipoprotein cholesterol, and high triglycerides had no incremental
John R Guyton et al.
Journal of the American College of Cardiology, 62(17), 1580-1584 (2013-08-07)
This study sought to examine the relationship between niacin treatment, lipoproteins, and cardiovascular (CV) outcomes in this secondary analysis of the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial. During a
Beat Müller et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 20(2), 181-195 (2003-10-11)
A novel methodology for establishing a pharmacological dose-effect relationship of methyl nicotinate, hexyl nicotinate and nicotinic acid acting as peripheral vasodilators in the skin following topical application is investigated. This methodology involves the estimation of the unbound drug concentration in
Paul M Lavigne et al.
Journal of the American College of Cardiology, 61(4), 440-446 (2012-12-26)
This study sought to assess the efficacy of niacin for reducing cardiovascular disease (CVD) events, as indicated by the aggregate body of clinical trial evidence including data from the recently published AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High
Martina Lukasova et al.
Trends in pharmacological sciences, 32(12), 700-707 (2011-09-29)
Nicotinic acid (niacin) has been used for decades to prevent and treat atherosclerosis. The well-documented antiatherogenic activity is believed to result from its antidyslipidemic effects, which are accompanied by unwanted effects, especially a flush. There has been renewed interest in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持